Evoke Pharma, Inc. (EVOK)
USD 3.09
(6.19%)
USD 3.09
(6.19%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.43 Million USD | 4.56% |
| 2022 | -7.78 Million USD | 4.48% |
| 2021 | -8.15 Million USD | 37.52% |
| 2020 | -13.04 Million USD | -82.37% |
| 2019 | -7.15 Million USD | 10.73% |
| 2018 | -8.01 Million USD | 28.64% |
| 2017 | -11.23 Million USD | -6.51% |
| 2016 | -10.54 Million USD | 10.78% |
| 2015 | -11.81 Million USD | 10.13% |
| 2014 | -13.15 Million USD | -405.42% |
| 2013 | -2.6 Million USD | -29.93% |
| 2012 | -2 Million USD | 17.07% |
| 2011 | -2.41 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.22 Million USD | 18.5% |
| 2024 Q1 | -1.5 Million USD | 20.48% |
| 2023 FY | -7.43 Million USD | 4.56% |
| 2023 Q3 | -1.6 Million USD | 10.14% |
| 2023 Q2 | -1.78 Million USD | 17.2% |
| 2023 Q4 | -1.88 Million USD | -17.74% |
| 2023 Q1 | -2.15 Million USD | -26.05% |
| 2022 FY | -7.78 Million USD | 4.48% |
| 2022 Q2 | -2.11 Million USD | -3.0% |
| 2022 Q1 | -2.05 Million USD | -32.56% |
| 2022 Q3 | -1.91 Million USD | 9.47% |
| 2022 Q4 | -1.7 Million USD | 10.6% |
| 2021 Q3 | -1.84 Million USD | 14.94% |
| 2021 FY | -8.15 Million USD | 37.52% |
| 2021 Q1 | -2.59 Million USD | -17.26% |
| 2021 Q2 | -2.16 Million USD | 16.27% |
| 2021 Q4 | -1.54 Million USD | 16.13% |
| 2020 Q3 | -2.07 Million USD | 70.14% |
| 2020 Q2 | -6.96 Million USD | -288.3% |
| 2020 Q1 | -1.79 Million USD | -25.95% |
| 2020 FY | -13.04 Million USD | -82.37% |
| 2020 Q4 | -2.2 Million USD | -6.23% |
| 2019 Q4 | -1.42 Million USD | 12.98% |
| 2019 Q1 | -1.96 Million USD | -11.39% |
| 2019 Q2 | -2.12 Million USD | -7.81% |
| 2019 Q3 | -1.63 Million USD | 22.93% |
| 2019 FY | -7.15 Million USD | 10.73% |
| 2018 Q4 | -1.76 Million USD | -16.15% |
| 2018 Q3 | -1.52 Million USD | 33.98% |
| 2018 FY | -8.01 Million USD | 28.64% |
| 2018 Q1 | -2.41 Million USD | 9.08% |
| 2018 Q2 | -2.3 Million USD | 4.61% |
| 2017 FY | -11.23 Million USD | -6.51% |
| 2017 Q4 | -2.65 Million USD | 28.17% |
| 2017 Q3 | -3.7 Million USD | -28.11% |
| 2017 Q2 | -2.88 Million USD | -45.92% |
| 2017 Q1 | -1.98 Million USD | 14.8% |
| 2016 Q3 | -2.16 Million USD | 25.14% |
| 2016 FY | -10.54 Million USD | 10.78% |
| 2016 Q2 | -2.89 Million USD | 8.09% |
| 2016 Q1 | -3.15 Million USD | -23.59% |
| 2016 Q4 | -2.32 Million USD | -7.14% |
| 2015 Q4 | -2.55 Million USD | 4.0% |
| 2015 Q2 | -3.16 Million USD | 8.15% |
| 2015 Q1 | -3.44 Million USD | -18.21% |
| 2015 Q3 | -2.65 Million USD | 16.02% |
| 2015 FY | -11.81 Million USD | 10.13% |
| 2014 Q2 | -3.49 Million USD | -19.48% |
| 2014 Q3 | -3.82 Million USD | -9.43% |
| 2014 Q4 | -2.91 Million USD | 23.73% |
| 2014 FY | -13.15 Million USD | -405.42% |
| 2014 Q1 | -2.92 Million USD | -84.88% |
| 2013 Q4 | -1.58 Million USD | -225.54% |
| 2013 Q1 | -332.03 Thousand USD | 49.84% |
| 2013 FY | -2.6 Million USD | -29.93% |
| 2013 Q2 | -203.42 Thousand USD | 38.73% |
| 2013 Q3 | -485.59 Thousand USD | -138.71% |
| 2012 FY | -2 Million USD | 17.07% |
| 2012 Q1 | -502.42 Thousand USD | 0.0% |
| 2012 Q2 | -360.33 Thousand USD | 28.28% |
| 2012 Q3 | -477.74 Thousand USD | -32.58% |
| 2012 Q4 | -661.91 Thousand USD | -38.55% |
| 2011 FY | -2.41 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | 95.223% |
| Theratechnologies Inc. | -10.62 Million USD | 30.075% |
| Safety Shot Inc | -12.18 Million USD | 39.012% |
| Cosmos Health Inc. | -21.83 Million USD | 65.962% |
| Cronos Group Inc. | -81.37 Million USD | 90.868% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 103.555% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 81.021% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 159.328% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -110.699% |
| ProPhase Labs, Inc. | -21.61 Million USD | 65.618% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -58.07% |
| Dynavax Technologies Corporation | -37.02 Million USD | 79.932% |
| Radius Health, Inc. | -3.92 Million USD | -89.322% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -195.437% |
| Alvotech | -354.86 Million USD | 97.906% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -55.286% |
| Alpha Teknova, Inc. | -35.56 Million USD | 79.105% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 95.338% |
| SCYNEXIS, Inc. | 72.66 Million USD | 110.226% |
| Harrow Health, Inc. | 580 Thousand USD | 1381.188% |
| Biofrontera Inc. | -22.67 Million USD | 67.232% |
| DURECT Corporation | -36.88 Million USD | 79.853% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -41.03% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 115.82% |
| OptiNose, Inc. | -22.74 Million USD | 67.334% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 158.826% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 50.795% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -19.644% |
| SIGA Technologies, Inc. | 83.62 Million USD | 108.886% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 179.637% |
| Shineco, Inc. | -17.06 Million USD | 56.458% |
| Phibro Animal Health Corporation | 53.31 Million USD | 113.938% |
| Procaps Group S.A. | 52.32 Million USD | 114.202% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 12.814% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -56.878% |
| Viatris Inc. | 766.2 Million USD | 100.97% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -55.286% |
| Rockwell Medical, Inc. | -6.67 Million USD | -11.408% |
| Incannex Healthcare Limited | -30.04 Million USD | 75.264% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -41.433% |
| Tilray Brands, Inc. | -174.74 Million USD | 95.748% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 104.451% |
| PetIQ, Inc. | 60.01 Million USD | 112.382% |
| Silver Spike Investment Corp. | 7.34 Million USD | 201.237% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.962% |
| Journey Medical Corporation | -2.07 Million USD | -258.461% |
| Alimera Sciences, Inc. | -1.47 Million USD | -405.159% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 45.431% |
| Assertio Holdings, Inc. | -243.53 Million USD | 96.949% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -26.11% |
| Embecta Corp. | 221.5 Million USD | 103.355% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 62.938% |
| Procaps Group, S.A. | 38.97 Million USD | 119.067% |
| PainReform Ltd. | -9.58 Million USD | 22.466% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 94.609% |
| Hempacco Co., Inc. | -8.81 Million USD | 15.676% |
| Talphera, Inc. | -16.88 Million USD | 56.002% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 108.475% |
| Alvotech | -354.86 Million USD | 97.906% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 102.038% |
| Kamada Ltd. | 10.06 Million USD | 173.836% |
| Indivior PLC | -4 Million USD | -85.772% |
| Currenc Group, Inc. | -6.64 Million USD | -11.814% |
| Flora Growth Corp. | -50.35 Million USD | 85.243% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 62.938% |
| Evolus, Inc. | -49.23 Million USD | 84.907% |
| HUTCHMED (China) Limited | 18.37 Million USD | 140.44% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 103.772% |
| Akanda Corp. | -10.05 Million USD | 26.071% |